TY  - ADVS
AU  - Markman,Maurie
TI  - Surrogate endpoints of efficacy
T2  - Cancer therapy : latest thinking in efficacy and toxicity,
PY  - 2018///
CY  - London
PB  - Henry Stewart Talks
KW  - Antineoplastic agents
KW  - Cancer
KW  - Chemotherapy
KW  - Treatment
KW  - Evaluation
KW  - Clinical trials
KW  - Outcome assessment (Medical care)
KW  - Antineoplastic Agents
KW  - administration & dosage
KW  - therapeutic use
KW  - Biomarkers
KW  - Clinical Trials as Topic
KW  - Endpoint Determination
KW  - Goals
KW  - Neoplasms
KW  - prevention & control
KW  - therapy
KW  - Treatment Outcome
N1  - Animated audio-visual presentation with synchronized narration; Title from title frames; Updated version of a talk first published in 2009; Contents: Improvement in overall survival must be considered the single most important goal of any new antineoplastic strategy -- Also increasingly recognized that in well-defined settings it is reasonable to employ other objectively measurable endpoints of efficacy such as time to symptomatic disease progression -- The rationale for the use of surrogate or alternative endpoints in cancer clinical trials -- Examples of where such endpoints may be appropriately utilized; Access restricted to subscribers
UR  - https://hstalks.com/bs/1117/
UR  - https://hstalks.com/bs/p/385/
ER  -